By Mill Chart
Last update: Aug 13, 2025
Allogene Therapeutics Inc (NASDAQ:ALLO) reported its second-quarter 2025 financial results, posting a net loss of $50.9 million, or $0.23 per share, compared to analyst expectations of a loss of $0.28 per share. Revenue for the quarter was $0, missing the estimated $1.86 million. Despite the revenue shortfall, the narrower-than-expected loss appears to have been received positively by the market, with shares rising nearly 1% in after-hours trading.
The stock’s modest after-hours gain suggests investors were more focused on the improved bottom-line performance rather than the lack of revenue. Over the past month, shares have declined ~16.9%, likely due to broader market conditions and sector-specific pressures. The immediate post-earnings uptick indicates some relief that losses were not as steep as feared.
Beyond the financials, Allogene highlighted progress across its clinical programs:
Allogene did not provide specific revenue or EPS guidance for upcoming quarters, but analysts currently project:
Given the lack of formal guidance, the market’s reaction remains tied to clinical progress rather than near-term financial performance.
Allogene’s Q2 results reflect a company still in heavy investment mode, with clinical milestones taking precedence over revenue generation. The beat on EPS and a solid cash position may reassure investors, but the lack of revenue remains a concern. The stock’s muted but positive after-hours reaction suggests cautious optimism, particularly given the progress in key trials.
For more detailed earnings and estimates, visit Allogene Therapeutics' earnings page.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
1.1
+0.03 (+2.8%)
Find more stocks in the Stock Screener